Alcohol and HIV: What Clinicians Need to Know
(2nd Edition – 2019 Update)

Trainer Guide
## Table of Contents

- **Background Information** ................................................................. 3
- **What Does the Training Package Contain?** ................................. 4
- **What Does This Trainer’s Guide Contain?** ..................................... 4
- **How is This Trainer’s Guide Organized?** ....................................... 4
- **General Information about Conducting the Training** .................... 4
- **Materials Needed to Conduct the Training** ..................................... 5
- **Overall Trainer Notes** ................................................................. 5
- **Icon Key** .................................................................................. 5
- **Slide-By-Slide Trainer Notes** ....................................................... 6
  - Introductory Material and Key Terms (Slides 1-15) .......................... 7-21
  - Part 1: Mechanism of Action and Acute and Chronic Effects (Slides 16-32) ................... 22-42
  - Part 2: Patterns and Trends in the Use of Alcohol in the United States (Slides 33-48) .... 43-61
  - Part 3: The Intersection of Alcohol and HIV/AIDS (Slides 49-74) ............................ 62-95
  - Part 4A: Assessing for Alcohol Use among Your Patients Living with HIV (Slides 75-85) .......................................................... 95-107
  - Part 4B: Effective Behavioral Treatment Interventions for AUD (Slides 86-94) ............ 108-116
  - Part 4C: Effective Medical Treatment Interventions for AUD (Slides 95-115) ............. 117-138
  - Concluding Thoughts (Slides 116-126) ........................................... 138-146
- **Acknowledgements** ...................................................................... 147
- **SBI Interactive Exercise Handout (for slides 82-83)** ..................... 148
Background Information

The purpose of this introductory training is to provide HIV clinicians (including, but not limited to physicians, dentists, nurses, and other allied medical staff, therapists and social workers, and counselors, specialists, and case managers) with a detailed overview of alcohol abuse and the behavioral and medical approaches for treating individuals with an alcohol use disorder. The introductory training (which was initially developed in 2012) has been updated, and includes a 126-slide PowerPoint presentation, Trainer Guide, and a companion 2-page fact sheet. The duration of the training is approximately 3 hours, if the trainer chooses to present all of the slides. The training duration can be shortened slightly by eliminating select slides. For example, slides 50-58 represent a general introduction of HIV/AIDS, and can be eliminated if your audience already has a broad knowledge base with regards to HIV/AIDS education.

“Test Your Knowledge” questions have been inserted at the beginning and end of the presentation to assess a change in the audience’s level knowledge after the key content has been presented. An answer key is provided in the Trainer’s notes for slides 7-11 and slides 121-125. Poll Everywhere, or a similar audience polling system can be utilized, if available, when facilitating the Test Your Knowledge question sessions. For more information, visit: https://www.polleverywhere.com/.

In addition, a series of case studies (slide 74 and slide 115) and additional questions (slides 96-99) have been inserted throughout the presentation to encourage dialogue among the training participants, and to illustrate how the information presented can be used clinically.

The cover image credit is a purchased image from Adobe Stock, 2019.
What Does the Training Package Contain?

- PowerPoint Training Slides (with notes)
- Trainer’s Guide with detailed instructions for how to convey the information and conduct the interactive exercises, and a participant handout for the SBI interactive exercise that appears on slides 82-83
- Two-Page Fact Sheet for HIV Clinicians

What Does This Trainer’s Guide Contain?

- Slide-by-slide notes designed to help the trainer effectively convey the content of the slides themselves
- Supplemental information for select content to enhance the quality of instruction
- Suggestions for facilitating questions and group discussions.

How is This Trainer’s Guide Organized?

For this guide, text that is shown in bold italics is a “Note to the Trainer.” Text that is shown in normal font relates to the “Trainer’s Script” for the slide.

It is important to note that several slides throughout the PowerPoint presentation contain animation, some of which is complicated to navigate. Animations are used to call attention to particular aspects of the information or to present the information in a stepwise fashion to facilitate both the presentation of information and participant understanding. Becoming acquainted with the slides, and practicing delivering the content of the presentation are essential steps for ensuring a successful, live training experience.

General Information about Conducting the Training

The training is designed to be conducted in medium-sized groups (20-35 people). It is possible to use these materials with larger groups, but the trainer may have to adapt the small group exercises and discussions to ensure that there is adequate time to cover all of the content.
Materials Needed to Conduct the Training

- Computer with PowerPoint software installed (2010 or higher version recommended) and LCD projector to show the PowerPoint training slides.

- When making photocopies of the PowerPoint presentation to provide as a handout to training participants, it is recommended that you print the slides three slides per page with lines for notes. Select “pure black and white” as the color option. This will ensure that all text, graphs, tables, and images print clearly.

- Flip chart paper and easel/white board, and markers/pens to write down relevant information, including key case study discussion points.

Overall Trainer Notes

It is critical that, prior to conducting the actual training, the trainer practice using this guide while showing the slide presentation in Slideshow Mode in order to be prepared to use the slides in the most effective manner.

Icon Key

<table>
<thead>
<tr>
<th>Image</th>
<th>Note to Trainer</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image1.png" alt="Person Speaking" /></td>
<td>Note to Trainer</td>
<td>Activity</td>
</tr>
<tr>
<td><img src="image2.png" alt="Books" /></td>
<td>References</td>
<td>Image Credit</td>
</tr>
<tr>
<td><img src="image3.png" alt="Camera" /></td>
<td>Video Source</td>
<td></td>
</tr>
</tbody>
</table>
Alcohol and HIV: What Clinicians Need to Know
(2nd Edition, 2019 Update)

Slide-By-Slide Trainer Notes

The notes below contain information that can be presented with each slide. This information is designed as a guidepost and can be adapted to meet the needs of the local training situation. Information can be added or deleted at the discretion of the trainer(s).
The purpose of this introductory training is to provide HIV clinicians (including, but not limited to physicians, dentists, nurses, and other allied medical staff, therapists and social workers, and counselors, specialists, and case managers) with a detailed overview of alcohol abuse and the behavioral and medical approaches for treating individuals with an alcohol use disorder. The introductory training (which was initially developed in 2012) has been updated, and includes a 126-slide PowerPoint presentation, Trainer Guide, and a companion 2-page fact sheet. The duration of the training is approximately 3 hours, if the trainer chooses to present all of the slides. The training duration can be shortened slightly by eliminating select slides. For example, slides 50-58 represent a general introduction of HIV/AIDS, and can be eliminated if your audience already has a broad knowledge base with regards to HIV/AIDS education.

“Test Your Knowledge” questions have been inserted at the beginning and end of the presentation to assess a change in the audience’s level knowledge after the key content has been presented. An answer key is provided in the Trainer’s notes for slides 7-11 and slides 121-125.
Poll Everywhere, or a similar audience polling system can be utilized, if available, when facilitating the Test Your Knowledge question sessions. For more information, visit: https://www.polleverywhere.com/.

In addition, a series of case studies (slide 74 and slide 115) and additional questions (slides 96-99) have been inserted throughout the presentation to encourage dialogue among the training participants, and to illustrate how the information presented can be used clinically.

**IMAGE CREDIT**
Slide 2: Training Collaborators

This PowerPoint presentation, Trainer Guide, and companion fact sheet were developed by Beth Rutkowski, MPH (Director of Training of UCLA ISAP and Co-Director of the Region 9 PSATTC) and Thomas E. Freese, PhD (Co-Director of UCLA ISAP and Co-Director of the Pacific Southwest ATTC) through supplemental funding provided by the Pacific AIDS Education and Training Center, based at Charles R. Drew University of Medicine and Science. We wish to acknowledge Thomas Donohoe, MBA, Sandra Cuevas, Maya Gil Cantu, MPH, and Kevin-Paul Johnson, from the LA Region PAETC.
Part 1 of the training will provide an overview of the mechanism of action of alcohol and its acute and chronic effects. Part 2 of the training will focus on the epidemiology of alcohol use. Part 3 of the training will focus on the intersection of alcohol use and HIV. Finally, Part 4 of the training will focus on evidence-based screening and assessment procedures and behavioral and medical treatments for alcohol use disorders.

IMAGE CREDIT
Purchased image, Fotolia, 2018.
In an effort to break the ice and encourage group interaction, take a few minutes to ask training participants to briefly share the answers to these four questions. You can ask for several volunteers to share their responses, if the size of your audience prevents all participants from sharing.

If the group is too large for formal introductions, the trainer can quickly ask participants the following two questions to gauge their work setting and professional training:

1. How many [case managers, LMFTs or LCSWs, counselors, administrators, psychologists, physicians, PAs, nurse practitioners, nurses, medical assistants, dentists, etc.] are in the room? Did I miss anyone? (elicit responses)

(Notes for Slide 4, continued)

**Slide 4: Introductions**

*Image Credit*

**Slide 5: Educational Objectives**

*Image Credit*

**Educational Objectives**

- Define at least three key terms related to alcohol and at-risk drinking.
- Review the neurobiology/medical consequences, and epidemiology of alcohol use.
- Discuss the intersection of alcohol use and HIV/AIDS.
- Explain the key concepts of at least three effective behavioral and three effective medical interventions for alcohol use disorders.

*Briefly review each of the educational objectives with the audience.*
Slide 6: Test Your Knowledge

The purpose of the following five questions is to test the current level of alcohol and HIV knowledge amongst training participants. The five questions are formatted as either multiple choice or true/false questions. Read each question and the possible responses aloud, and give training participants time to jot down their response before moving on to the next question. Do not reveal the answers to the questions until the end of the training session (when you re-administer the questions that appear on slides 121-125).

IMAGE CREDIT
Purchased Image, n.d.
Slide 7: Test Your Knowledge – Question 1

At-risk drinking levels are the same, regardless of the drinker’s age or gender:
A. True
B. False

Read the question and choices, and review audience responses out loud.

IMAGE CREDIT

Slide 8: Test Your Knowledge – Question 2

The four main neurotransmitters related to alcohol are:
A. Dopamine, serotonin, GABA, and glutamate
B. Serotonin, GABA, endorphins, and norepinephrine
C. Endogenous opioids, glutamate, GABA, and dopamine
D. Endogenous opioids, glutamate, endorphins, and norepinephrine

Read the question and choices, and review audience responses out loud.

IMAGE CREDIT
Read the question and choices, and review audience responses out loud.

IMAGE CREDIT
The goal(s) of effective medication-assisted treatment for alcohol use disorder should be:
A. Short-term stabilization and withdrawal
B. A treatment of last resort
C. Ongoing maintenance
D. A and C
E. None of the above

**Slide 11: Test Your Knowledge – Question 5**

*Read the question and choices, and review audience responses out loud.*

**IMAGE CREDIT**
Slide 12: Defining Some Key Terms

This slide includes the definitions for several alcohol-related key terms that will be used throughout the presentation.

For more information on each term, please visit:

- **At-risk drinking:** NIAAA  

- **Standard drink:** NIAAA  

- **Hazardous drinking:** JAMA  
  [https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/1105638](https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/1105638)
This slide continues the list of definitions for several alcohol-related key terms that will be used throughout the presentation.

For more information on each term, please visit:

- **Harmful drinking**: JAMA
  (https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/1105638)

- **Binge drinking**: NIAAA
  (https://www.cdc.gov/alcohol/factsheets/binge-drinking.htm)

- **Alcohol use disorder**: NIAAA
Slide 14: How Do We Define Risk?

We ask our clients and patients screening questions to identify risk. But how is risk defined? The U.S.-based National Institute on Alcohol and Alcoholism (NIAAA) defines risk as drinking more than the recommended limits. According to this image, the recommended limit for men is no more than 4 drinks per day and no more than 14 drinks per week. For women, the limit is no more than 3 drinks per day and no more than 7 drinks per week. Older adults (men and women over the age of 65) are generally advised to have no more than 3 drinks on a day and 7 per week.

According to research, women show signs of alcohol-related problems at lower drinking levels than men. Women, on average, weigh less than men, and women have less water in their bodies than men (this is relevant because alcohol disperses in body water).
Slide 14: How Do We Define Risk?

REFERENCE
Slide 15: What is a Standard Drink?

**ACTIVITY**

*Standard drink demonstration (use plastic glasses and water with food coloring to show the audience a standard-sized pour of regular beer, table wine, and 80-proof distilled spirits)*

People have different personal definitions of what exactly constitutes an alcoholic “drink.” The National Institute on Alcohol Abuse and Alcoholism has developed a definition of a standard drink. A standard drink can be a 12 ounce beer, 8-9 ounces of malt liquor, 5 ounces of table wine, 3-4 ounces of fortified wine, 2-3 ounces of cordial, 1.5 ounces of brandy, or 1.5 ounces of spirits such as vodka, gin, or scotch. So, a drink for one person may be a “40-ouncer” of beer, which, if you use NIAAA’s definition of a standard drink, would equal 3 1/3 standard drinks. It is very important for alcohol dependent patients to understand what is meant by “a drink” when you are assessing the level of risk associated with their alcohol consumption.
**Slide 15: What is a Standard Drink?**

**REFERENCE**

**Slide 16: [TRANSITION SLIDE] Part 1 – Mechanism of Action and Acute and Chronic Effects**

This next section (Part 1) of the presentation provides more detail on the mechanism of action of alcohol and its acute and chronic effects on the user’s brain and body.
Slide 17: How Does Alcohol Produce Intoxication?

This brief, 2-minute video explains the mechanism of action of alcohol. How alcohol acts on the central nervous system to produce intoxication is still poorly understood. In this video, the narrator summarizes current perspectives on the neural effects of alcohol, emphasizing its recognized actions on GABA and glutamate receptors along with some of its systemic effects.

VIDEO SOURCE
https://www.youtube.com/watch?v=1D2yrNcGuo.

TRANSCRIPT:

Welcome to 2 minute neuroscience, where I explain neuroscience topics in 2 minutes or less. In this installment I will discuss alcohol. How alcohol acts in the central nervous system is still poorly understood. Two of the best known effects of alcohol, however, are its actions on GABA and glutamate receptors. Alcohol increases GABA activity at a subtype of the GABA receptor known as GABAa.
Slide 17: How Does Alcohol Produce Intoxication?

The mechanism by which this occurs is still not clear, but it is thought that alcohol may act as a positive allosteric modulator, meaning it binds to a site on the receptor that is separate from where GABA binds, and increases the effect GABA has when it binds to the receptor itself. The immediate effect of this action typically is the inhibition of neural firing. Alcohol also inhibits the activity of glutamate receptors. Again, the mechanism for this is not fully understood but because glutamate is generally excitatory, inhibition by alcohol initially leads to the reduction of neural activity. A long list of other synaptic actions have been linked to alcohol, including (but not limited to): activation of serotonin receptors, enhancement of glycine receptor function, inhibition of adenosine reuptake, inhibition of calcium channels, activation of potassium channels, and modulation of nicotinic acetylcholine receptor function.

It’s not clear, however, how relevant each of these effects are to the human use of alcohol. There are also some large-scale effects associated with alcohol. For example, alcohol stimulates dopamine transmission in the mesolimbic dopamine pathway—an action thought to be associated with the reinforcement of alcohol consumption.
Slide 17: How Does Alcohol Produce Intoxication?

Alcohol affects motor coordination and balance, potentially in part through its influence on neurons in the cerebellum. And it inhibits long-term potentiation and other mechanisms of synaptic plasticity in the hippocampus, which may contribute to its memory-disrupting effects.

REFERENCES


Slide 18: Four Main Neurotransmitters are Relevant to Alcohol (1)

As was demonstrated in the brief video, two processes occur simultaneously when alcohol is consumed. One process acts on the naturally occurring opioids in the brain (which deaden pain and cause feelings of euphoria), and dopamine (which makes things feel good). The next slide shows the other process.

Slide 19: Four Main Neurotransmitters are Relevant to Alcohol (2)

Two processes occur simultaneously when alcohol is consumed. As you saw on the previous slide, the first process acts on the naturally occurring opioids in the brain (which deaden pain and cause feelings of euphoria), and dopamine (which makes things feel good). The second process operates on glutamate (the excitatory neurotransmitter that wakes you up) and GABA (the inhibitory neurotransmitter that slows you down). The next few slides detail each process separately.
Slide 20: Alcohol Neuronal Activity (1)

In the first process, a person drinks alcohol and this causes the release of the endogenous, or naturally occurring, opioids to be released in the pleasure centers of the brain. This in turn, causes the release of dopamine. Since dopamine makes the person feel good, drinking is reinforced and this increases the likelihood of repeated use. A subsequent section of this training will review two medications used to treat alcohol directly by addressing the pleasurable effects of alcohol.

Slide 21: Alcohol Neuronal Activity (2)

At the same time that alcohol is making the person feel good, a second process occurs. When the person drinks, GABA (the inhibitory neurotransmitter) is released and this slows down the brain. This results in the symptoms of intoxication from alcohol, such as difficulty with coordination, drowsiness, slurring speech, etc. With repeated use, the brain attempts to correct for the overabundance of GABA by creating more receptors for glutamate. This increases the effectives of glutamate, and the system is energized and balance is restored.
GABA is the brain’s main inhibitory neuron. When it is stimulated, the brain slows down. For instance, when you are relaxing in the evening and start to get sleepy, GABA is beginning to surge forward preparing you to sleep.

Glutamate is the major excitatory neuron. Glutamate surges to alert the brain of the need for increased activity making neurotransmitters ready to fire.

GABA and Glutamate should work in balance with each other, so that one or the other surges forward depending on need, maintaining function and overall balance in the brain.

When alcohol is introduced, it causes a surge in GABA and with repeated drinks, the glutamate system becomes less able to keep up and maintain balance.
(Notes for Slide 22, continued)

Slide 22: The Excitatory ad Inhibitory Balance (1)

Over time, as alcohol continues to be consumed, the brain’s compensatory mechanisms kick in and works to restore balance by creating more [upregulating] glutamate [NMDA] receptors.

[Click once to move animation forward]
This restores balance again.

[Advance to next slide]

IMAGE CREDIT
Purchased Image, n.d.
Now in order to feel that intoxicating feeling, more alcohol needs to be consumed.

This again results in a surge in GABA,

overwhelming the glutamate system again.

This process repeating over time results in what we know as tolerance. You will hear more about tolerance on slide 24.

The compensatory mechanisms continue,

more glutamate [NMDA] receptors are again added to system and balance is again restored.
Slide 23: The Excitatory and Inhibitory Balance (2)

[Advance to next slide]

IMAGE CREDIT
Purchased Image, n.d.
Now we have a brain that is held in balance with alcohol boosting GABA, and a supercharged glutamate system with greatly upregulated numbers of glutamate [NMDA] receptors.

What happens when a person stops drinking?

GABA levels fall to normal or below. Because there are way too many NMDA receptors that are not being counterbalanced, the brain goes into overdrive and is over excited in many areas. This leads to the experience of withdrawal such as shakiness, sweating, loss of appetite, agitation, restlessness, irritability, nausea or vomiting, anxiety or nervousness, fast heart rate, tremor, disorientation, headache, insomnia, or seizures.
Slide 24: The Excitatory and Inhibitory Balance (3)

IMAGE CREDIT
Purchased Image, n.d.

Slide 25: Tolerance

As was previously mentioned and demonstrated, alcohol consumption interferes with many bodily functions and affects behavior. And after chronic alcohol consumption, the drinker often develops tolerance to at least some of alcohol's effects. Tolerance means that after continued drinking, consumption of a constant amount of alcohol produces a lesser effect or increasing amounts of alcohol are necessary to produce the same effect.

IMAGE CREDIT
Purchased Image, n.d.
Alcohol relaxes the brain and body, which some people find pleasurable. Many people find that moderate drinking (a drink or two of alcohol a day) helps relieve stress, encourages relaxation and acts as an appetite stimulant. Its acute effects, however, can also alter mood and lead to physical, psychological and social problems. Even small amounts of alcohol can have an effect on your coordination, reactions, and judgments. Binge drinking can lead to poor coordination, vomiting, exaggerated emotional reactions (including sadness, tearfulness, anger, and aggression) and can lead to unconsciousness. Women who are pregnant or planning to become so, are advised to avoid alcohol. A hangover, which may include a headache, dry mouth, feeling sick, and tired, is a common consequence of heavy drinking. These effects are caused by dehydration and toxicities. Extremely heavy drinking can lead to coma and even death.
Alcohol withdrawal refers to symptoms that may occur when a person who has been drinking too much alcohol suddenly stops. Alcohol withdrawal symptoms usually occur within 5-10 hours after the last drink, but can occur days later. Symptoms get worse in 48-72 hours, and may persist for weeks. People with moderate to severe symptoms of alcohol withdrawal may require inpatient treatment at a hospital or other facility that treats alcohol withdrawal. You will be watched closely for hallucinations and other signs of delirium tremens.

Treatment may include: (1) monitoring of blood pressure, body temperature, heart rate, and blood levels of different chemicals in the body; (2) IV fluids or medications; and (3) sedation using benzodiazepines until withdrawal is complete. Those with mild to moderate symptoms of withdrawal may be treated in an outpatient program.

Mild to moderate withdrawal symptoms can be safely and effectively managed as outpatients using non-pharmacologic therapy or benzodiazepines to treat symptoms. Daily contact with the treating clinician and a friend or family member to administer medications is optimal for these patients.
Benzodiazepines should be used on a short-term basis and should be tapered as soon as possible. Delirium tremens is a medical emergency associated with untreated alcohol withdrawal. It occurs 3-14 days after drinking is stopped. Delirium tremens include agitation, restlessness, gross tremor, disorientation, fluid and electrolyte imbalance, sweating and high fevers, visual hallucinations, and paranoia. The estimated prevalence of DTs is < 5% of alcohol dependent patients, but it is possible for DTs to lead to death.
Long-term, chronic alcohol use affects almost every organ system of the body, potentially resulting in serious illnesses, including liver disease, impaired heart function (known as cardiomyopathy), and inflammation of the pancreas (called pancreatitis). Even one-time acute alcohol consumption, such as binge drinking, can temporarily alter the activity of many organ systems. Furthermore, heavy alcohol consumption by a pregnant woman can harm her fetus and lead to fetal abnormalities ranging from mild learning deficits to full-blown fetal alcohol syndrome (FAS).

**IMAGE CREDIT**
Slide 29: Alcohol Use Disorder and Depressive Symptoms

In 2019, McHugh and Weiss published a review paper focused on alcohol use disorder (AUD) and depressive disorders. The aim of the article was to describe the prevalence, course, and treatment of co-occurring AUD and depressive disorders. This slide features data on the co-occurrence of AUD and depressive disorders (major depressive disorder and dysthymia).

REFERENCE
The Dangers of Binge Drinking

A myriad of health problems are associated with binge drinking. This slide lists several of them. Unintentional injuries include car crashes, falls, burns, and alcohol poisoning. Violence includes homicide, suicide, intimate partner violence, and sexual assault. Poor pregnancy outcomes include miscarriage and stillbirth. Chronic diseases include high blood pressure, stroke, heart disease, and liver disease. Cancers include breast, mouth, throat, esophagus, liver, and colon.

REFERENCES
Centers for Disease Control and Prevention. (2018). Fact Sheets – Binge Drinking. Available at:


(Notes for Slide 30, continued)

REFERENCES, continued

Slide 31: Critical Signs and Symptoms of an Alcohol Overdose

This slide presents the various signs and symptoms that someone may exhibit if they are experiencing an alcohol overdose.

REFERENCE
In May 2013, the American Psychiatric Association issued the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). This slide details the important differences between the previous version (DSM-IV) and current version (DSM-5).

The DSM-5 criteria for AUD include: (1) had times when you ended up drinking more, or longer, than you intended; (2) more than once wanted to cut down or stop drinking, or tried, but could not; (3) spent a lot of time drinking or being sick or getting over aftereffects; (4) wanted a drink so badly you could not think of anything else; (5) found that drinking or being sick from drinking often interfered with taking care of your home or family or caused job or school troubles; (6) continued to drink even if it was causing trouble with family and friends; (7) gave up or cut back on activities that were important or interesting to you, or gave you pleasure in order to drink; (8) more than once got into situations while drinking or after drinking that increased chance of getting hurt; (9) continued to drink even though it was making you feel depressed or anxious, added to another health problem, or after having a memory blackout;
Slide 32: Alcohol Use Disorder – A Comparison Between DSM-IV and DSM-5

(10) had to drink much more than you once did to get the effect you want or found that your usual number of drinks had much less effect than before; and (11) found that when the effects of alcohol were wearing off, you had withdrawal symptoms.

The severity of an AUD is defined as:

Mild – presence of 2-3 symptoms

Moderate – presence of 4-5 symptoms

Severe – presence of 6+ symptoms

REFERENCE


The next portion of the presentation (Part 2) will provide training participants with a detailed overview of patterns and trends in alcohol use in the United States. No single drug abuse indicator can tell the full story of the extent or impact of prescription opioids. Therefore, data from several available indicators are presented in an attempt to paint a comprehensive picture of who abuses alcohol, and the populations in which abuse and dependence is most prevalent.
Slide 34: Prevalence of Alcohol Use Disorder in the United States

This slide presents annual and lifetime prevalence data from the National Epidemiologic Survey on Alcohol and Related Conditions III (NESARC). The survey provides data on the prevalence, correlates, psychiatric comorbidity, associated disability, and treatment of DSM-5 AUD diagnoses. Face to face interviews are conducted with a representative sample of non-institutionalized, civilian adults (age 18 and older). In 2012-13, a total of 36,309 individuals were interviewed. Prevalence was highest for a variety of sub-populations, included Native Americans, younger individuals, Whites, and men.

REFERENCE
Current, Binge, and Heavy Alcohol Use among People Aged 12 and Older, 2018

The National Survey on Drug Use and Health (NSDUH) is an annual survey that provides national indicators of substance use and mental health among people aged 12 or older in the civilian, noninstitutionalized population of the United States. Results are provided for the overall category of people aged 12 or older and by age subgroups. In 2018, approximately 139.8 million Americans aged 12 or older were current alcohol users, 67.1 million were binge drinkers in the past month, and 16.6 million were heavy drinkers in the past month. Nearly half of current alcohol users were binge drinkers (48.0 percent), and 1 in 8 current alcohol users were heavy drinkers (11.8 percent). Among binge drinkers, about 1 in 4 (24.7 percent) were heavy drinkers.
Slide 35: Current, Binge, and Heavy Alcohol Use among People Aged 12 and Older, 2018

REFERENCE
Approximately 4.9 million people aged 12 and older used alcohol for the first time in 2018. In other words, on each day in 2018, approximately 13,400 people initiated alcohol use. This graph provides the number of alcohol initiates by age group and survey year. The numbers were greatest among those individuals aged 12 to 17.

REFERENCE
As was previously stated, there were an estimated 139.8 million current alcohol users aged 12 or older in 2018, corresponding to slightly more than half of the people in the population (51.1%). The 2018 estimate of past month alcohol use was similar to the estimates in most years from 2002 to 2017. An estimated 9.0% of adolescents aged 12 to 17 in 2018 were current alcohol users, which corresponds to 2.2 million adolescents who drank alcohol in the past month. The percentage of adolescents who were current alcohol users in 2018 was lower than the percentages in most years from 2002 through 2017. Although the estimate of current alcohol use among adolescents decreased between 2002 and 2018, about 1 in 11 adolescents were current alcohol users in 2018. In 2018, an estimated 55.1% of young adults aged 18 to 25 were current alcohol users, which corresponds to about 18.8 million young adults. The percentage of young adults in 2018 who drank alcohol in the past month was lower than the percentages in 2002 through 2016, but it was similar to the percentage in 2017. More than half of adults aged 26 or older in 2018 (55.3%) were current alcohol users.
Slide 37: Current Alcohol Use by People Aged 12 and Older, 2002-2018

This percentage corresponds to about 118.8 million adults in this age group who drank alcohol in the past month. In each year between 2002 and 2018, slightly more than half of adults aged 26 or older were current alcohol users (ranging from 52.5% to 56.5%).

REFERENCE

Slide 38: Alcohol Use Related to Other Substance Use, Major Depressive Disorder, and Serious Mental Illness

This bar graph shows the relationship of alcohol use related to past year marijuana use, past year opioid misuse, past year cocaine use, past year methamphetamine use, past year major depressive episode, and past year serious mental illness. Those individuals who had past month heavy alcohol use were most likely to report past month use of all other substances, as well as past year major depressive episode or past year serious mental illness than those who used alcohol in the past month but no heavy use, and those who did not use alcohol at all in the past month.

REFERENCE
Slide 39: Trends in Lifetime Use of Alcohol, 2018

Monitoring the Future is an ongoing study of the behaviors, attitudes, and values of Americans from adolescence through adulthood. Each year, a total of approximately 50,000 8th, 10th and 12th grade students are surveyed (12th graders since 1975, and 8th and 10th graders since 1991). In addition, annual follow-up questionnaires are mailed to a sample of each graduating class for a number of years after their initial participation. The Monitoring the Future Study has been funded under a series of investigator-initiated competing research grants from the National Institute on Drug Abuse, and conducted at the Survey Research Center in the Institute for Social Research at the University of Michigan.

This bar chart features data from the 2018 Monitoring the Future Survey. At the far left is the percentage of 8th (23.5%), 10th (43%), and 12th (58.5%) graders who reported any lifetime alcohol use. In the middle is the percentage of 8th (9.2%), 10th (26.2%), and 12th (42.9%) graders who reported ever being drunk. To the right is the percentage of 8th (18%), 10th (35.9%), and 12th (50.4%) graders who reported lifetime consumption of flavored alcohol beverages.
Slide 39: Trends in Lifetime Use of Alcohol, 2018

REFERENCE
Slide 40: Trends in Current Use of Alcohol, 2018

This bar chart features additional data from the 2018 MTF survey. At the far left is the percentage of 8th (8.2%), 10th (18.6%), and 12th (30.2%) graders who reported any alcohol use in the past 30 days. In the middle is the percentage of 8th (2.1%), 10th (8.4%), and 12th (17.5%) graders who reported being drunk in the past 30 days. To the right is the percentage of 8th (4.9%), 10th (11.8%), and 12th (18.1%) graders who reported past 30 day consumption of flavored alcohol beverages.

REFERENCE
Slide 41: Characteristics of Binge Drinkers

This slide presents data for binge drinking by age group, according to findings from the 2015 Youth Risk Behavior Surveillance System and Behavioral Risk Factor Surveillance System.

REFERENCES


Slide 42: Binge Alcohol Use among Young People

With regards to binge drinking, according to the National Survey on Drug Use and Health, 5.3% of youth aged 12 to 17 reported binge alcohol use in the past month in 2018. Binge alcohol use was higher among females than males and higher among non-Hispanic white and American Indian/Alaska Native youth. As a sake of comparison, among young adults aged 18 to 25, 36.9% reported binge alcohol use in the past month.

REFERENCE
Slide 43: Some Good News – Decreases in First Use of Alcohol Seen among Young People

This slide shows data on the first use of alcohol, marijuana, and cigarettes (also known as past-year initiation). In 2017, 9.3% of youth aged 12-17 used alcohol for the first time. This is a significant decrease from the rate seen in 2002 (10.5%). Significant decreases were also seen with marijuana use and cigarette use.

REFERENCE
Between 2007 and 2017, five substance groups accounted for between 93% and 97% of the primary substances reported among treatment admissions aged 12 years and older: alcohol, opiates, marijuana/hashish, cocaine, and methamphetamine/amphetamines. However, the proportions of admissions by primary substance used changed considerably during the period for most substances. The most frequently reported primary substances in 2017 were: opiates (34%), alcohol (29%), marijuana/hashish (13%), stimulants (12%), and cocaine (5%), accounting for 93% of all admissions aged 12 years and older.

The proportion of admissions with alcohol use reported as the primary substance ranged between 39-40% from 2007 through 2010, before declining to 29% in 2017. The average age at admission among alcohol-only admissions was 43 years, whereas the average age among admissions for primary use of alcohol with secondary drug use was 39 years. Almost two thirds (63%) of alcohol-only admissions aged 12 years or older were non-Hispanic Whites, 14% were of Hispanic origin, and 14% were non-Hispanic Blacks.
Slide 44: Primary Substance of Abuse at Time of Admission, 2006-2016

Among admissions for primary alcohol with secondary drug use, 56% were non-Hispanic Whites, 22% were non-Hispanic Blacks, and 14% were of Hispanic origin.

REFERENCE
About 9 in 10 people (91.6%) with a past-year alcohol use disorder did not receive specialty treatment and did not perceive a need for treatment for their alcohol use.

REFERENCE
Slide 46: Patterns of Alcohol-Related Injuries and Deaths

This slide presents statistics on alcohol-related injuries and deaths, both nationally and internationally. Alcohol is the third leading preventable cause of death in the United States, following tobacco (1st) and physical inactivity (2nd).

REFERENCE


Slide 47: Alcohol and the Human Body

This slide presents statistics on the effects of alcohol on the human body, most notably the liver. With regards to the increase in alcohol-related liver disease deaths between 1999 and 2016, the highest increase (about 10.5% each year) was seen among adults aged 25-34.
Slide 48: The Relationship between Blood Alcohol Concentration and Impairment

This graphic presents the relationship between rising blood alcohol concentration (BAC) and the level of impairment in the individual. As BAC increases, so do the effects of alcohol. Even at very low BACs a person can exhibit mild impairment in speech, memory, attention, etc.

REFERENCE

Slide 49: [TRANSITION SLIDE] Part 3 – The Intersection of Alcohol and HIV/AIDS

The next portion of the presentation (Part 3) corresponds to the relationship between alcohol use and HIV/AIDS.

Slide 50: HIV in the U.S. and Dependent Areas

This image depicts the breakdown of new HIV diagnoses (in 2017). With regards to the most prevalent transmission category, the majority of new HIV diagnoses were among gay and bisexual men, followed by heterosexual men and women. At the end of 2015, there were an estimated 1,122,900 people living with HIV in the United States.

REFERENCE

Slide 51: New HIV Diagnoses in the U.S. and Dependent Areas for the Most Affected Populations, 2017

This graph shows the number of new HIV diagnoses for the most affected sub-populations. The highest numbers were seen among black men who have sex with men (MSM), followed by Hispanic/Latino male-to-male sexual contact, White MSM, and black heterosexual women.

REFERENCE

The age group with the greatest number of new HIV diagnoses was the 25-34 age group, followed by 13-24 year olds and then 35-44 year olds.

REFERENCE
Slide 53: What Has Happened Over Time with Regards to HIV Diagnoses?

Reductions were seen in many transmission categories, including among people who inject drugs (PWID), gay and bisexual men who inject drugs, heterosexuals, and white gay and bisexual men. The category in which the number of HIV diagnoses increased was among Hispanic/Latino gay and bisexual men. Diagnoses remained stable among gay and bisexual men overall and among African American gay and bisexual men.

REFERENCE
Slide 54: The Importance of HIV Testing

This CDC infographic presents data on HIV testing gathered as part of the 2016-2017 Behavioral Risk Factor Surveillance System. One in seven people with HIV do not know they are infected with the virus. More screening is needed, as evidenced by the fact that 60% of U.S. adults have never had an HIV test, and 70% of those with higher HIV risk were not tested in the past year. Everyone should be tested at least once in their lives, and those with higher risk should be tested annually.

REFERENCE

The HIV Care Continuum, also known as the HIV Treatment Cascade, is a model developed by Dr. Edward Gardner and colleagues in 2011 that outlines the sequential steps of HIV medical care that people living with HIV go through from initial diagnosis to viral suppression. The top image depicts the care continuum. The bottom image shows where improvements are needed in the care continuum. According to recent data available from the CDC, of the 1.2 million people living with HIV in the U.S. in 2011, 86% were diagnosed, 40% were engaged in HIV medical care, 37% were prescribed ART, and 30% had achieved viral suppression. Stated in another way, only 3 in 10 people living with HIV had the virus under control.

REFERENCE
Slide 56: What is Needed to Achieve Suppression?

In an analysis conducted by the CDC in 2014, among the nearly 840,000 people who had not achieved viral suppression (~70%), 20% did not know they were infected, 66% had been diagnosed but were not engaged in regular HIV medical care, 4% were in HIV care, but not prescribed ART, and 10% had been prescribed ART, but had not yet achieved viral suppression.

“This underscores the importance of continued and intensified efforts to reach more people with testing and to make sure that those with the virus receive prompt, ongoing care and treatment to help them live longer, healthier lives and prevent the spread of HIV to others.”

REFERENCE

Slide 57: What Does More Recent Data Tell Us?

For every 100 people living with HIV in 2015, 63 received some HIV care; 49 were retained in care; and 51 were virally suppressed. At the end of 2015, there were 1.12 million people living with HIV in the United States. Of those, about 15% had not received a diagnosis (162,500). Young people are most likely to be unaware of their HIV status. In 2016, there were 15,807 deaths among people diagnosed with HIV in the United States.

REFERENCE

Slide 58: 90-90-90 – An Ambitious Target to End the AIDS Epidemic by 2020

By 2020, 90% of all people living with HIV will know their HIV status. By 2020, 90% of all people with diagnosed HIV infection will receive sustained antiretroviral therapy. By 2020, 90% of all people receiving antiretroviral therapy will have viral suppression.

REFERENCE
Slide 59: Alcohol and HIV: An Overview (1)

On July 10, 2019, the U.S. Department of Health and Human Services released Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. In a section on considerations for antiretroviral use in special patient populations, key considerations and recommendations were provided for people with SUD and HIV. This slide and the next slide feature those key considerations and recommendations. Additional information is available at: https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/22/substance-use-disorders-and-hiv.

REFERENCE

A complex relationship exists between alcohol use and HIV. Alcohol use is common among people at risk for HIV and has a central modifiable effect on their health outcomes, especially now that those with HIV are living longer with the disease. Up to 50% of adults with HIV infection have a history of alcohol problems (3,4). Alcohol use among people with HIV can affect medication adherence and antiretroviral resistance, as well as increase risky sexual behavior.

Heterosexual sex is now a primary route for HIV transmission. Alcohol use is one of the factors that increases the risk of HIV transmission among heterosexuals. Particularly among women, a strong association has been seen between alcohol and other drug abuse, infection with HIV, and progression to AIDS (5). Although additional studies are needed to further define alcohol use patterns among infected and at-risk people, it is clear that alcohol use is closely intertwined with the spread of HIV.
Slide 60: Alcohol and HIV: An Overview (2)

A history of heavy alcohol use has been correlated with a lifetime tendency toward high-risk sexual behaviors, including multiple sex partners, unprotected intercourse, sex with high-risk partners (e.g., people who inject drugs, sex workers), and the exchange of sex for money or drugs (6-9).

Additional Information for the Trainer(s)

People who drink alcohol tend to delay getting tested for HIV and, if they do test positive, tend to postpone seeking treatment. And when receiving HIV treatment, alcohol abusers may have difficulty following a complex medication regimen.

REFERENCES

REFERENCES, continued


REFERENCES, continued


Slide 61: Alcohol Use and Risky Sexual Behaviors

With regards to the relationship between alcohol use and ART adherence, studies have shown both temporal and dose-related relationships. ART is more likely to be missed on a given drinking day and day after drinking, with a stronger association on heavy/binge drinking days. Studies have also demonstrated an association between unhealthy alcohol use and the loss of durable viral suppression, greater time spent with a viral lode of >1,500 copies/mL after ART initiation, increased risk of viral rebound, lower retention in care, and increased mortality.

Research suggests that people who strongly believe that alcohol enhances sexual arousal and performance are more likely to practice risky sex after drinking. Further, some people deliberately use alcohol during sexual encounters to provide an excuse for socially unacceptable behavior or to reduce conscious awareness of risk.
Slide 61: Alcohol Use and Risky Sexual Behaviors

REFERENCE

Slide 62: How Does Substance Use Affect a Person Living with HIV?

Substance use in general can have several negative impacts on a person living with HIV, including a weakened immune system, damage to the liver, interactions with HIV medicines, and issues with adherence to medication regimens.

REFERENCE
Clinicians may often miss alcohol problems in patients with clinically stable HIV infection and those without evidence of liver disease, which underscores the importance of screening all patients for alcohol use. The role of the primary care clinician in the management of the patient who abuses alcohol or is dependent on alcohol is as follows: (1) identify the problem; (2) present the diagnosis; (3) work to engage and motivate the patient; and (4) participate in the initiation of treatment and continuum of care.

REFERENCES

HIV-positive people who drink heavily and who are not on anti-HIV drugs tend to have lower CD4 counts (a measure of immune system function) than moderate drinkers. While the same difference in CD4 count isn’t true for heavy drinkers who are taking anti-HIV drugs, they are more likely to miss doses of their treatment than those who abstain from drinking alcohol.

REFERENCE

Alcohol, ART, and the Liver

Alcohol use has been associated with decreased adherence to anti-retroviral therapy (ART). Studies have varied in the measurement of alcohol consumption, and a dose-response relationship has not been defined; however, hazardous or risky alcohol use has been shown to negatively influence adherence by causing patients to miss doses or take medications off schedule (1-4). In one study, hazardous and binge drinkers were more likely to have detectable viral load (5), which may be attributable to diminished adherence. Alcohol intake is a modifiable risk factor for decreased adherence.

Clinicians should routinely ask patients about alcohol consumption during adherence assessments. Screening for alcohol use can be accomplished with a few simple questions to identify patients who will benefit from further interventions. HIV patients who have liver disease are sometimes with the grim choice of continuing ART to prevent the progression of the virus to AIDS—thereby risking further liver damage—or stopping ART to prevent liver damage and progressing to AIDS.

Research suggests that alcohol may interfere directly with ART medications used for HIV, essentially blocking their effectiveness (6).
Moreover, patients who drink are nine times more likely to fail to comply with their medication regimens compared with sober patients (7-8). When HIV-infected drinkers fail to take their medications or do not take them correctly, it can lead to a higher viral load and an increasing likelihood that the virus will become resistant to the therapy.

ART, alcohol consumption, and HIV infection can be harmful in other ways as well. HIV patients typically experience declines in organ function earlier in life than do uninfected people. And because people with HIV tend to drink heavily well into their middle and older years, these organs are even more at risk for injury. For example, both HIV infection and certain types of ART medications increase a person’s risk for heart disease, because they change the balance of different fats—such as cholesterols—in blood, induce inflammation, and affect the blood-clotting process. Both excessive alcohol use and infection with hepatitis C virus further enhance the risk. Also, the medicines used to treat cholesterol problems can be particularly harmful when taken by patients with liver damage from alcohol abuse or hepatitis C virus.
Heavy alcohol consumption (more than six drinks per day) has been linked to heart disease in HIV-infected people; thus, stopping or cutting down on their drinking may help to reduce the risk of heart disease (9).

**Additional Information for the Trainer(s)**

Alcohol can also damage the liver, and a healthy liver is important for the body to process some antiretroviral medicines effectively. The blood fat increases caused by some anti-HIV drugs can be made worse by heavy drinking. There are no significant interactions between any of the currently available anti-HIV drugs and alcohol but alcohol can react badly with certain medicines (e.g. rifampicin, rifabutin, metronidazole). It is important to check with your pharmacist that alcohol is safe to drink with any medicines you are prescribed. All patients with hepatitis C virus (HCV) infection who use alcohol should be educated about the effects of alcohol on the course of HCV and HIV infection. Patients with HCV and heavy alcohol intake have increased progression of hepatic fibrosis and increased risks of cirrhosis, hepatocellular carcinoma, and death.
REFERENCE


REFERENCES, continued


REFERENCES, continued
Scientists do not yet know if alcohol and HIV together raise the risk for injury to the lung. However, studies using animals suggest that this combination does indeed increase the risk for problems. Lung infections remain a major cause of illness and death in those with HIV. Opportunistic infections are rare viruses that infect only people whose immune systems are weakened by a condition like HIV infection.

REFERENCES


Advances in imaging techniques have revealed another organ at risk for HIV and alcohol injury—the brain. Alcohol can act directly on the brain to reduce inhibitions and diminish risk perception. Alcohol may also increase the severity of AIDS-related brain damage, which is characterized in its severest form by profound dementia and a high death rate.

REFERENCES


Slide 68: Indirect Effects of Alcohol on Increasing HIV Risk

This slide reviews several possible indirect effects of alcohol on increasing HIV risk, including the settings in which alcohol is often abused, the high-risk behaviors that coincide with the abuse of alcohol, and the use of alcohol in combination with other illicit substances and prescription medications.
Alcohol consumption is associated with decreased antiretroviral adherence, and decreased adherence results in poorer outcomes. However the magnitude of alcohol’s impact on survival is unknown. Our objective was to use a calibrated and validated simulation of HIV disease to estimate the impact of alcohol on survival. Braithwaite and colleagues incorporated clinical data describing the temporal and dose-response relationships between alcohol consumption and adherence in a large observational cohort (N=2,702). Individuals were categorized as nondrinkers (no alcohol consumption), hazardous drinkers (consume 5 or more standard drinks on drinking days), and nonhazardous drinkers (consume less than 5 standard drinks on drinking days). The results suggest that alcohol is an underappreciated yet modifiable risk factor for poor survival among individuals with HIV.
Slide 69: The Impact of Alcohol Consumption on the Survival of Individuals Living with HIV

REFERENCE
Slide 70: Alcohol Treatment as HIV Prevention

Excessive drinking within the HIV-infected population is associated with numerous adverse effects; thus, interventions to prevent alcohol misuse in this population are urgently needed. Decreasing alcohol use among HIV patients not only reduces the medical and psychiatric consequences associated with alcohol consumption but also decreases other drug use and HIV transmission. Thus, alcohol and other drug abuse treatment can be considered primary HIV prevention as well.

REFERENCE
Slide 71: Medications for HIV Infection

Doctors recommend a combination of HIV drugs from at least two of the main classes. This combination is called highly active antiretroviral therapy (HAART). It helps combat new resistant strains of the virus that emerge as HIV makes copies of itself. HAART also decreases the rate of opportunistic infections.
Slide 72: Considerations for Antiretroviral Use in Special Patient Populations – SUD and HIV (1)

On July 10, 2019, the U.S. Department of Health and Human Services released Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. In a section on considerations for antiretroviral use in special patient populations, key considerations and recommendations were provided for people with SUD and HIV. This slide and the next slide feature those key considerations and recommendations. Additional information is available at: https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/22/substance-use-disorders-and-hiv.

REFERENCE

Slide 73: Considerations for Antiretroviral Use in Special Patient Populations – SUD and HIV (2)

On July 10, 2019, the U.S. Department of Health and Human Services released Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. In a section on considerations for antiretroviral use in special patient populations, key considerations and recommendations were provided for people with SUD and HIV. This slide and the previous slide feature those key considerations and recommendations. Additional information is available at: https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/22/substance-use-disorders-and-hiv.

REFERENCE

Case Study #1

Read the case study aloud. Ask participants to break into pairs or small groups (depending on the size of the audience), and spend 5-10 minutes discussing the questions. De-brief as a full group for 5-10 minutes. Ask for volunteers to briefly share responses to the two questions.

Slide 75: [TRANSITION SLIDE] Part 4A – Assessing for Alcohol Use among Your Patients Living with HIV

This next section of the presentation (Part 4A) features information on screening, brief intervention, and referral to treatment (SBIRT).
SBIRT has the potential to save lives and reduce costs. It is estimated that unhealthy and unsafe alcohol and drug use result in more than 100,000 deaths each year, and costs to society are more than $600 billion annually.

SBIRT includes screening for both alcohol and drug use; supports the view that behavioral health is part of one’s overall health; and follows a population health approach that emphasizes prevention and early intervention. And although brief intervention for other substances has not been proven effective, it has been suggested that BI may need to be conducted over the course of many more visits in order to be effective.
In summary, SBIRT consists of a few basic competencies. Ask everyone. Don’t assume you know who is engaging in risky use. Might it be the middle aged pastor, the 65 year retired teacher, or the 22 y/o medical student? Assist individuals to identify reasons to change using MI techniques. I know you heard about MI in the previous ECHO, but we’ll do a quick review of how MI is used in SBIRT in a moment. Achieve successful engagement—whether to pursue a treatment plan or not—according to the patient’s choice. And in order to do all of this, we all have to become better informed about what constitutes problematic use and to reflect on our own self-awareness- because the better we understand our own beliefs and emotional responses to risky alcohol use, the better able we will be to intervene effectively.
NIAAA developed a single-item screener to detect risky drinking, which has been validated and is used in many different primary care settings throughout the United States.

In medical diagnosis, test sensitivity is the ability of a test to correctly identify those with the disease (true positive rate), whereas test specificity is the ability of the test to correctly identify those without the disease (true negative rate).

REFERENCE
Slide 79: What Happens Next?

Many people are surprised by how few drinks can increase a person’s risk of developing a variety of health problems. These guidelines come from NIAAA and are based on studies looking at what level of alcohol intake is associated with increased risk for harm. If risky use is detected then assess for alcohol use disorder/risk for withdrawal syndrome. AUDIT (Alcohol Use Disorders Identification Test) can be helpful for data gathering. The AUDIT consists of 10 questions- self-administered or through an interview and addresses recent alcohol use, alcohol dependence symptoms, and alcohol-related problems.
The Alcohol Use Disorders Identification Test (AUDIT) was developed in the 1980s to identify alcohol use, abuse, and possible dependence. The AUDIT has 10 questions. It has been validated for use with diverse groups of people. It was originally designed for use in primary care settings, but can be used in mental health and college/university campus settings, as well.

Like most screens, the AUDIT gives you a score. The table on the slide provides action steps to take based on the score. The scores correlate to risk levels (low, moderate, and high). For example, a score of 0 to 7 is considered low risk and the appropriate response from the provider is to tell the patient he/she is at low risk, which is great. They should then encourage them to continue these low-risk behaviors. Scores between 8 and 19 suggests low to moderate risk. People in this risk range should receive a brief intervention focused on lowering their risk. People at the higher end of the moderate risk range—people who score 16 to 19—should be given a brief intervention and possibly the opportunity for brief treatment, which means additional counseling sessions. Again the goal is to help them to identify strategies to lower their risk of developing problems.
Slide 80: AUDIT – Alcohol Screener

A person at the very high end, with a score of 20 or higher, may have alcohol dependence. This person needs a referral to specialized care. A brief intervention should be conducted, but now the focus should be on helping the person to choose to accept and follow through on a referral to treatment.

A self-report version of the AUDIT is available at: https://www.drugabuse.gov/sites/default/files/files/AUDIT.pdf.
**Slide 81: Conducting a Brief Intervention**

This slide depicts an outline of the three steps of the FLO brief intervention and what happens at each step.

You start the conversation with **Feedback**, which involves giving patients their screening results and explaining what the results mean.

**Listen and Understand** is where you get into the motivational interviewing work of exploring the meaning of patients’ substance use, the pros and cons of using (also known as the decisional balance), and the important concern patients’ bring to the visit (which may or may not be substance use). During this step, you also assess what kinds of changes patients want to make and their level of readiness.

Lastly, **Options Explored** is where you discuss options that patients themselves identify to support change. You always want to encourage a follow up appointment so that we can check on the patients’ progress and provide support.
Slide 82: Let’s Practice!

Total length of activity = 20-25 minutes (7-10 minutes for each role play and 5-6 minutes for the de-brief.

Break into pairs and refer to the handout you received when you arrived at the training this morning. In the first part of the exercise, one person will role play an HIV provider (medical assistant, nurse, care manager, etc.) and the second person will role play a patient. For this part, please refer to the “Repeat After Me” handout. Like in a play, read the script exactly as it is written.

The intention of part 1 is to give you practice getting comfortable screening for and talking with your patients about their alcohol use, and how this use may impact their HIV care.
Slide 83: Now Try It Without a Script!

Total length of activity = 20-25 minutes (7-10 minutes for each role play and 5-6 minutes for the de-brief.

For this part, please refer to the “In Your Own Words” section of the handout. You’ll notice that instead of reading from a detailed script, you will need to follow the outline and repeat the exercise using your own words.

The intention of part 2 is to give you even more practice getting comfortable screening for and talking with your patients about their alcohol use, and how this use may impact their HIV care. Over time, it will become easier for you to use your own words to explore alcohol use and its impact on HIV treatment with your patients.

After part 2, spend a few minutes facilitating a full-group debrief with the audience. What did they like about this activity? What was challenging? How might they incorporate screening practices into their daily clinical work?
Approximately 5% of patients screened will score in the high-risk range for a potential substance use disorder. These patients have experienced serious medical, social, legal, or interpersonal problems associated with their substance use. Even though these patients have serious issues with substance use, it is still advisable to conduct a brief intervention with these patients before making a referral to specialty care. The reason for this is that the brief intervention can help the patient become more open to making a change. In order to help patients initiate treatment for substance use disorders, clinicians need to take an active role in the referral process. By “warm hand-off” we mean that clinicians make the transition to the treatment facility as smooth as possible for the patient.
In 2016, Chander and colleagues published an article on screening, knowledge, and behaviors related to alcohol interventions among HIV primary care providers. When you look at the data related to alcohol screening practices, you see that the majority of providers who responded to the cross-sectional survey always ask their patients whether they drink alcohol. That’s the good news. A smaller percentage always ask how much the drink on a drinking day and how frequently they drink. The bad news, or the area in which HIV primary care providers could use the most improvement, is in the use of a validated screening tool, such as the AUDIT. The majority of providers who responded to the survey rarely or never use a validated screening instrument. In fact, only 10% usually or always used a validated screening tool.
Slide 85: Alcohol Screening Practices among HIV Primary Care Providers

REFERENCE

The following section (Part 4B) pertains to effective behavioral treatment interventions for alcohol use disorders. Behavioral treatments help engage people in substance use disorders treatment, modifying their attitudes and behaviors related to alcohol and other drug use and increasing their life skills to handle stressful circumstances and environmental cues that may trigger intense craving for alcohol and drugs and prompt another cycle of compulsive use. Moreover, behavioral therapies can help people remain in treatment longer. Behavioral interventions—particularly, cognitive-behavioral therapy—have been shown to be effective for decreasing alcohol and drug use and preventing relapse. Length of time in treatment is the #1 predictor of a successful treatment experience. The longer you can keep a person engaged in treatment, the more likely he/she is to be successful. Treatment must be tailored to the individual patient’s needs in order to optimize outcomes—this often involves a combination of treatment, social supports, and other services. Early engagement techniques should be utilized to ensure that the client comes back for his/her group and individual sessions.
Slide 87: Behavioral Interventions

It is critical to emphasize that pharmacotherapies that are FDA-approved for treatment of alcohol use disorder should be used in conjunction with psycho-social-educational-spiritual therapy. Therefore, medications can be used as a part of treatment, but only one part.

Slide 88: Individualized Treatment Planning

Treatment planning involves a series of steps or special considerations, including:
(1) information gained during an initial assessment—physical history, treatment history, ability to manage medications; (2) role of the prescriber—does the patient have an existing relationship with a prescriber? Can the patient be appropriately monitored during treatment? Are there other medications that will interact?; (3) fits with the patient—effectiveness and treatment goals; (4) current level and type of substance abuse—interactions with other substances; (5) treatment compliance—previous experience with other pharmacotherapies and psychosocial therapy; and (6) ability to pay—insurance coverage, out-of-pocket, Medicare/Medicaid, etc.
Slide 89: Behavioral Approach #1 – Contingency Management (CM)

Contingency management is a tool to enhance treatment and facilitate recovery, and is used as an adjunct to other therapeutic clinical methods. CM targets specific behaviors that are part of a patient treatment plan. CM helps to celebrate the success of behavioral changes chosen by therapist and patient. CM can be used to help motivate patients through stages of change to achieve an identified goal.

Slide 90: Behavioral Approach #2 – Cognitive Behavioral Therapy (CBT)

CBT seeks to help patients recognize, avoid, and cope with the situations in which they are most likely to abuse drugs. Thoughts cause feelings and behaviors, not external things, like people, situations, and events. You can change the way we think to feel / act better even if the situation does not change.
Slide 91: Behavioral Approach #3 – Therapeutic Communities (TC)

Peer influence is used to help individuals learn and assimilate social norms and develop more effective social skills. Treatment staff and those in recovery are key agents of change. The second fundamental TC principle is "self-help," which implies that the individuals in treatment are the main contributors to the change process.

Slide 92: Behavioral Approach #4 – Motivational Interviewing (MI)

Compared with non-directive counseling, motivational interviewing is more focused and goal-directed. The examination and resolution of ambivalence is its central purpose, and the counselor is intentionally directive in pursuing this goal.

REFERENCE

The strategic goals of MI are to: (a) resolve ambivalence; (b) avoid eliciting or strengthening resistance; (c) elicit “Change Talk” from the client; (d) enhance motivation and commitment for change; and (e) help the client move through the Stages of Change. A series of MI micro-skills (which will be described on the next slide) can be used to move a patient/client through the Stages of Change to elicit and reinforce self-motivational statements (a.k.a., Change Talk).

Empathy may be the most crucial principle. It creates an environment conducive to change, instills a sense of safety and a sense of being understood and accepted, and reduces defensiveness. Empathy sets the tone within which the entire communication occurs. Without it, other components may sound like mechanical techniques. By developing discrepancy, the clinician can help the client to become more aware of the discrepancy between their addictive behaviors and their more deeply-held values and goals. Part of this is helping the client to recognize and articulate negative consequences of use. It is more effective if the client does this, not the clinician.
Slide 93: Basic MI Principles and Micro-Skills

With regards to rolling with resistance, in general, it is not helpful to argue with clients. Confrontation elicits defensiveness, which predicts a lack of change. It is particularly counter-therapeutic for a clinician to argue that there is a problem while the client argues that there isn’t one. The client does not need to accept a diagnostic label (e.g. “addict” or “alcoholic”) for change to occur.

Supporting self-efficacy can be conceptualized as a specific form of optimism, that is, a “can-do” belief in one’s ability to accomplish a particular task or change. This principle is crucial to help the client see and experience his/her own ability to make positive changes. Part of this is the clinician believing in the client’s ability to change.

Open-ended questions: (a) solicits information in a neutral way; (b) helps the person elaborate his/her own view of the problem and brainstorm possible solutions; (c) helps the therapist avoid prejudgments; (d) keeps communication moving forward; (e) allows the client to do most of the talking.
Affirmations should be focused on achievements of the individual, and are intended to: (a) support the individual’s persistence; (b) encourage continued efforts; (c) assist the individual in seeing the positive in the situation; and (d) support the individual’s proven strengths.

With reflective listening, one should: (a) listen to both what the person says and to what the person means; (b) check out assumptions; (c) create an environment of empathy (nonjudgmental); and (d) be aware of intonation (statement, not question). The clinician does not have to agree with the client.

Summaries capture both sides of the ambivalence (You say that ____________ but you also mentioned that ______________.) They demonstrate the clinician has been listening carefully. Summaries also prompt clarification and further elaboration from the person. They prepare clients to move forward.

REFERENCE

Acceptance includes the realization that drug addiction is a chronic, progressive disease over which one has no control, that life has become unmanageable because of drugs, that willpower alone is insufficient to overcome the problem, and that abstinence is the only alternative. Surrender involves giving oneself over to a higher power, accepting the fellowship and support structure of other recovering individuals, and following the recovery activities laid out by the 12-step program. While the efficacy of 12-step programs (and 12-step facilitation) in treating alcohol dependence has been established, the research on other abused drugs is more preliminary but promising for helping drug abusers sustain recovery. Twelve-step meeting dates, times, and locations can be found by visiting: [http://www.aa.org](http://www.aa.org) (Alcoholics Anonymous); [www.ca.org](http://www.ca.org) (Cocaine Anonymous); [www.na.org](http://www.na.org) (Narcotics Anonymous).
(Notes for Slide 94, continued)

Slide 94: Behavioral Approach #5 – 12-Step Facilitation Therapy

REFERENCES


Slide 95: [TRANSITION SLIDE] Part 4C – Effective Medical Treatment Interventions for Alcohol Use Disorders

The following section (Part 4C) pertains to effective medical treatment interventions for alcohol use disorder. Medication assisted treatment (MAT) is any alcohol use disorder treatment that includes an FDA-approved medication for the detoxification or maintenance treatment of alcohol use disorder. MAT may be provided in a Narcotic Treatment Program (NTP)/Opioid Treatment Program (OTP), a medication unit affiliated with an NTP/OTP, a physician’s office, or another health care setting. It includes comprehensive maintenance, medical maintenance, interim maintenance, detoxification, and medically supervised withdrawal. MAT increases the likelihood for cessation of alcohol.
Slide 96: The Use of Medicines to Treat AUD – What Do You Think – Question 1

This series of four questions is meant to gauge the beliefs (and potential bias) that the audience may have as it relates to medications for alcohol use disorders. Read the question and possible responses.

Medication can be an effective part of treatment. The idea that medications cannot be a part of substance use disorder treatment is held both by some treatment programs and by some individual practitioners. The reality is that medications are used in the treatment of many chronic, relapsing diseases, including SUD. Medical decisions must be made by trained and certified medical providers. It is important to remember that it is beyond the scope of practice for most substance use disorder treatment providers to make specific recommendations about the use of medications. All medical decisions should be made by a medical provider who has received specific training for the treatment of these conditions. Lastly, decisions about the use of medications should be based on an objective assessment of the individual client’s needs.
Additional Information for the Trainer(s)

The pharmacotherapies that are FDA-approved for treatment of alcohol and opioid use disorders should be used in conjunction with psycho-social-educational-spiritual therapy. Therefore, medications can be used as a part of treatment, but only one part.

It is important to emphasize the fourth key point. It is beyond the scope of practice for most substance use disorder treatment providers to make specific recommendations about medications. All medical decisions should be made by a medical provider who has received specific training for the treatment of these conditions.

IMAGE CREDIT
This series of four questions is meant to gauge the beliefs (and potential bias) that the audience may have as it relates to medications for alcohol use disorders. Read the question and possible responses.

The SUD treatment field needs to change its terminology to reflect current trends. “Drugs” are illicit psychoactive substances that are used to achieve a “high.” “Medications,” on the other hand, are available by prescription and are used to treat an illness, disorder, or disease. For example, millions of Americans use Zyban or nicotine patches to quit smoking, and this practice is widely encouraged by SUD treatment professionals. The goal of SUD treatment is to assist a person in stopping his or her compulsive use of drugs or alcohol and live a normal, functional life. If appropriately administered, medication-assisted treatment for SUD will not produce euphoric effects. Clinical data suggest that clients perform better in treatment when psycho-social-educational-spiritual therapy is combined with appropriate pharmacotherapies.
This myth relates to the previous myth and is one of the reasons that people believe that medications should not be a part of treatment. It is CRITICAL to emphasize that there is a difference between physical dependence on a substance and addiction. Anyone who takes certain kinds of medications (opioids, certain blood pressure meds, etc.) for an extended period of time will become physically dependent on the medication. This means that they will have withdrawal symptoms if they suddenly stop taking it. This does not mean that they are “addicted.”

IMAGE CREDIT
This series of four questions is meant to gauge the beliefs (and potential bias) that the audience may have as it relates to medications for alcohol use disorders. Read the question and possible responses.

AA/NA literature and founding members did not speak or write against using medications. In fact, AA/NA endorses participants to use medicines as prescribed for the treatment of medical conditions. In Chapter 9 of the Big Book, it says: “But this does not mean that we disregard human health measures. God has abundantly supplied this world with fine doctors, psychologists, and practitioners of various kinds. Do not hesitate to take your health problems to such persons. Most of them give freely of themselves, that their fellows may enjoy sound minds and bodies. Try to remember that though God has wrought miracles among us, we should never belittle a good doctor or psychiatrist. Their services are often indispensable in treating a newcomer and in following his case afterward.” [Chapter 9, p. 133 (emphasis added)].
Slide 98: The Use of Medicines to Treat AUD – What Do You Think? – Question 3

Additional Information for the Trainer(s)

This is the 1996 NA bulletin about methadone (available at: http://www.na.org/?ID=bulletins-bull29). It seems to indicate that people who attend NA meetings on methadone treatment should not speak and cannot lead meetings. Some NA groups are hostile to methadone treatment.

IMAGE CREDIT
This series of four questions is meant to gauge the beliefs (and potential bias) that the audience may have as it relates to medications for alcohol use disorders. Read the question and possible responses.

MAT is believed to be less effective than the research suggests, partly because our experience is based on the cases we’ve seen. The classic Clinician’s Illusion results from seeing "prevalence" sample – those currently with disease. The probability that a case will appear in a prevalence sample is proportional to its duration, thus clinicians thus biased toward cases of long duration and therefore greater intractability. In correctional settings we tend to be exposed most to severe cases and relapers who return often (“frequent flyers”). Patients who get better generally do not return to these settings. This situation produces a cognitive bias (availability bias) in which our pessimism is formed by remembering severe cases who relapse and return.
(Notes for Slide 99, continued)

Slide 99: The Use of Medicines to Treat AUD – What Do You Think? – Question 4

(SOURCE: NIDA, Treatment Approaches for Drug Addiction, retrieved from http://www.nida.nih.gov/Infofacts/TreatMeth.html). Formal clinical trials research has demonstrated the efficacy of each of the medications that have been FDA approved for addiction treatment. Some of this data will be reviewed during the remainder of this training. We tend to have a biased perception that patients who improve, leave the program and are forgotten, while those patients who do not improve return frequently and are remembered. This perception leads us to think that most patients do not improve...contrary to scientific data.

IMAGE CREDIT

Slide 100: How Can We Treat Alcohol Use Disorders Medically?

FDA-approved medications that are used to treat alcohol use disorders can help to reduce the agitation associated with post-acute withdrawal, block the pleasurable effects of alcohol, or discourage drinking by making the making the person sick if they drink.
Slide 101: FDA-Approved Medication #1 – Disulfiram

Disulfiram was approved by the FDA in 1951. It works by maintaining a state of enforced sobriety. It does this by making the individual sick if they consume alcohol. Disulfiram has no known addictive properties and there have been no reports of misuse.
When an individual drinks alcohol, it is broken down in three stages. First, the enzyme Alcohol Dehydrogenase converts alcohol into Acetaldehyde. Acetaldehyde is actually a toxic compound and therefore must be broken down further and eliminated. This occurs through the enzyme acetaldehyde dehydrogenase. It converts that acetaldehyde into acetate. Finally, Acetate is converted into water and carbon dioxide and eliminated from the body.

Disulfiram works by blocking the effect of acetaldehyde dehydrogenase. This causes a build up of the toxic acetaldehyde to levels 5-10 times greater than would normally occur if alcohol was breaking down normally. Since acetaldehyde is poisonous, a build-up of it produces a highly unpleasant series of symptoms, which is commonly referred to as the “disulfiram-alcohol reaction.” This reaction can be serious, and lead to respiratory suppression, heart attack, convulsions, and even death.
It’s important to note that this reaction will continue for as long as there is alcohol remaining in the blood. The symptoms can occur in some very sensitive patients even with extremely low concentrations of alcohol. The reaction will also continue for 1-2 weeks following the last dose of disulfiram.
Slide 104: What Does the Research Say about Disulfiram?

Previous research demonstrated that when compared to placebo, individuals receiving disulfiram were NOT more likely to maintain complete abstinence during the trial—probably because patients test themselves to see if alcohol does indeed make them sick. Results do demonstrate that those receiving disulfiram had fewer drinking days during the study, demonstrating its efficacy in helping people stay away from alcohol.

According to a 2014 meta-analysis conducted by Skinner and colleagues, they found that “blinded studies were incapable of distinguishing a difference between treatment groups, and thus were incompatible with disulfiram research. Based on results with open-label studies, disulfiram is a safe and efficacious treatment compared to other abstinence supportive pharmacological treatments or to no disulfiram in supervised studies for problems of alcohol abuse or dependence.”
Slide 104: What Does the Research Say about Disulfiram?

REFERENCE


Slide 105: FDA-Approved Medication #2 – Acamprosate

Acamprosate was approved in 2004 for the maintenance of abstinence by reducing post-acute withdrawal symptoms. It has no known addictive properties.

Acamprosate is covered by most major insurance carriers, Medicare, and Medicaid. The VA will cover the medication, but only if naltrexone is contraindicated for the patient. Forest Laboratories also offers a patient assistance program for those who cannot afford the medication. Dosing may be an issue for some patients. It requires taking two fairly large tablets three times per day. The tablets have a coating on them that allows them to pass through the stomach intact and then release the medication in the small intestines.
Slide 106: How Does Acamprosate Work?

It is not known exactly how acamprosate works, but it is thought be a glutamate receptor modulator. To understand what this means, let’s review how alcohol works. When alcohol is repeatedly consumed the depressive effects of alcohol are counteracted by increasing the glutamate receptors. This energizes the system and counteracts the alcohol present in the system.
Slide 107: What Does the Research Say about Acamprosate?

Four studies were considered by the FDA in approving acamprosate for use. In summary, when compared to placebo, individuals treated with acamprosate were able to maintain complete abstinence throughout the trial more frequently. They had a greater reduction in the total number of drinking days during the trial, and among those who had a relapse, those treated with acamprosate were able to regain complete abstinence after only one relapse more frequently.

REFERENCES


(Notes for Slide 107, continued)

Slide 107: What Does the Research Say about Acamprosate?

REFERENCES, continued


Slide 108: FDA-Approved Medication #3 – Naltrexone

Naltrexone hydrochloride is approved for the treatment of alcohol or opioid use disorder and works by blocking the effects of opioids and reducing the pleasurable effects of alcohol. It has no known addictive properties, but should only be administered to individuals who are abstinent from opioids (as administering naltrexone will invoke opioid withdrawal symptoms in patients who are physically dependent on opioids).

Naltrexone is covered by most public and private insurers. Dosing requires taking one pill once per day and it can be crushed and/or mixed with food. Abstinence from opioids for at least 7-10 days is essential to avoid causing withdrawal symptoms. Abstinence from alcohol is not required prior to initiation.

Slide 109: How Does Naltrexone Work?

Naltrexone works as an opioid receptor antagonist. This means that it binds strongly to the opioid receptor. It does not cause an effect at the receptor site and block other opioids from stimulating the receptors. This prevents intoxicating effects from self-administered opioids. It also diminishes the pleasurable effects of alcohol.
Slide 110: What Does the Research Say about Naltrexone?

Research on using naltrexone for alcohol, demonstrated that when compared to placebo, naltrexone users were not able to maintain complete abstinence more frequently, but it did result in a great reduction in overall use during the course of the study.

Slide 111: FDA-Approved Medication #4 – Extended-Release Naltrexone

Extended-release injectable naltrexone was approved in 2006 to treat patients with an alcohol use disorder, and in 2010 to treat patients with an opioid use disorder. The medication provides the opportunity for patients to take it once a month, as opposed to daily dosing required by some of the medications. The dose is one 380-mg injection deep in the muscle of the buttock. It must be administered by a healthcare professional and should alternate buttocks each month.

The medication the blocks the opioid receptors for 4 weeks—this would require 28 doses of oral naltrexone. Once it is in, there is no way to remove it. Therefore, the person is prevented from experiencing the effects of opioids and/or alcohol.
Slide 112: How Does Extended-Release Naltrexone Work?

Naltrexone works as an opioid receptor antagonist. This means that it binds strongly to the opioid receptor. It does not cause an effect at the receptor site and block other opioids from stimulating the receptors. This prevents intoxicating effects from self-administered opioids. It also diminishes the pleasurable effects of alcohol.

REFERENCE

Slide 113: What Does the Research Say about Extended-Release Naltrexone?

Research on the extended release formulation of naltrexone, demonstrated that when compared to placebo, patients receiving the medication did not maintain complete abstinence more frequently, but they did have a greater reduction in the total number of drinking days/opioid use. When used for alcohol, those with a 7-day abstinence period prior to the first injection had fewer heavy drinking days.

During the clinical trials, there was an increase in suicidal ideation (but not attempts) noted in patients receiving the extended release naltrexone. Counselors working with these patients should closely monitor for suicidal ideation. Additionally, if opioids are required for pain relief (in the case of emergency, for instance), it will require significantly more and the patient is likely to need respiratory support. Patients receive naltrexone in either oral or injectable form should be encouraged to carry an information card documenting that they are receiving the medication.
Slide 114: Medications for AUD and Potential Interaction with ARV Medications

This table includes the three FDA-approved medications for the treatment of alcohol use disorder and the corresponding potential interactions with anti-retroviral medications. Of note is disulfiram, in that you should use with caution when prescribing ARV oral solution that contains ethanol and/or propylene glycol.

Slide 115: Case Study #2

Read the case study aloud. Ask participants to break into pairs or small groups (depending on the size of the audience), and spend 5-10 minutes discussing the questions. De-brief as a full group for 5-10 minutes. Ask for volunteers to briefly share responses to the two questions.

Slide 116: [TRANSITION SLIDE]

Concluding Thoughts

This final section of the presentation features take-home points for clinicians, key resources, and post-test questions to gauge key learning among training participants.
It is important to be familiar with local resources, including substance use disorders treatment facilities, 12-step meetings, and mental health resources. Alcohol use impacts the user’s brain and body, but can be treated. Continue to dialogue with patients about their alcohol use and the importance of continued HIV care.

**Additional Information for the Trainer(s)**

Patients with an alcohol use disorder should be engaged in a treatment programs. HIV clinicians should be familiar with local resources for SUD/AUD treatment and related psychiatric care, including inpatient or residential treatment, outpatient treatment, and support groups such as Alcoholics Anonymous. In addition, clinicians should assess for potential withdrawal symptoms. Clinicians should also consider the use of pharmacotherapy if warranted. Medications are available that target neurotransmitters involved in the reinforcing effects of alcohol use. Pharmacotherapy for AUD in combination with behavioral counseling can reduce relapse and help maintain abstinence. HIV clinics offer a number of advantages as a site for alcohol pharmacotherapy.
Slide 117: Take Home Points for Clinicians (1)

These clinics are involved in long-term patient care, are generally characterized by integration of a variety of specialty services (e.g., psychiatric and ob/gyn services), and have access to funding for prescription medications. Further, many HIV clinics use intensive case management models that promote outreach to and retention of patients who are often challenging to treat.

Slide 118: Take Home Points for Clinicians (2)

It is important to be familiar with local resources, including substance use disorders treatment facilities, 12-step meetings, and mental health resources. Alcohol abuse impacts the user’s brain and body, but can be treated. Continue to dialogue with patients about their alcohol use and the importance of continued HIV care.
If you suspect that someone has had an alcohol overdose, call 911 immediately. This slide presents practical tips for you to consider as you wait for first responders to arrive.

REFERENCE

The purpose of the following four questions is to see how much the audience learned about the factual questions that were first queried at the beginning of the training.
Slide 121: What Did You Learn? – Question 1

ANSWER KEY
#1 – correct response is B (False)

IMAGE CREDIT

Slide 122: What Did You Learn? – Question 2

ANSWER KEY
#2 – correct response is C (Endogenous opioids, glutamate, GABA, and dopamine)

IMAGE CREDIT
Slide 123: What Did You Learn? – Question 3

**ANSWER KEY**

#3 – correct response is A (True)

**IMAGE CREDIT**

Slide 124: What Did You Learn? – Question 4

**ANSWER KEY**

#4 – correct response is D (All of the above)

**IMAGE CREDIT**

What Did You Learn? – Question 5

The goal(s) of effective medication-assisted treatment for alcohol use disorder should be:
A. Short-term stabilization and withdrawal
B. A treatment of last resort
C. Ongoing maintenance
D. A and C
E. None of the above

ANSWER KEY
#5 – correct response is D (A and C)

IMAGE CREDIT
This concludes the presentation. Thank the participants for their time and address any last-minute questions about the content. Encourage participants to reach out to the Pacific Southwest ATTC or Pacific AETC, should they have questions or concerns following the training session.

Prepared in 2019 by: Pacific Southwest Addiction Technology Transfer Center

11075 Santa Monica Boulevard, Suite 200
Los Angeles, California 90025

T: (310) 267-5408
F: (310) 312-0538

pacificsouthwestca@attcnetwork.org

At the time of writing, Thomas E. Freese, Ph.D. served as the Principal Investigator and Director of the HHS Region 9, Pacific Southwest Addiction Technology Transfer Center, based at UCLA Integrated Substance Abuse Programs and Beth A. Rutkowski, MPH served as Co-Director of the HHS Region 9, Pacific Southwest Addiction Technology Transfer Center. Humberto M. Carvalho, MPH, served as the ATTC Government Project Officer.
Dr. Louis Trevisan currently serves as Director of the Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration. The opinions expressed herein are the views of the authors and do not reflect the official position of the Pacific Southwest ATTC/SAMHSA-CSAT. No official support or endorsement of the Pacific Southwest ATTC/SAMHSA-CSAT for the opinions described in this document is intended or should be inferred.
Acknowledgements

Prepared in 2019 by: Pacific Southwest Addiction Technology Transfer Center
11075 Santa Monica Boulevard, Suite 200
Los Angeles, California 90025
T: (310) 267-5408
F: (310) 312-0538
pacificsouthwestca@attcnetwork.org

At the time of writing, Thomas E. Freese, Ph.D. served as the Principal Investigator and Director of the HHS Region 9, Pacific Southwest Addiction Technology Transfer Center, based at UCLA Integrated Substance Abuse Programs and Beth A. Rutkowski, MPH served as Co-Director of the HHS Region 9, Pacific Southwest Addiction Technology Transfer Center. Humberto M. Carvalho, MPH, served as the ATTC Government Project Officer. Dr. Louis Trevisan currently serves as Director of the Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration. The opinions expressed herein are the views of the authors and do not reflect the official position of the Pacific Southwest ATTC/SAMHSA-CSAT. No official support or endorsement of the Pacific Southwest ATTC/SAMHSA-CSAT for the opinions described in this document is intended or should be inferred.
Attachment #1
Handout for Interactive Activity (Slides 82-83)
Alcohol and HIV: What Clinicians Need to Know

Interactive Exercise – Conducting an Alcohol Brief Intervention (Slides 82-83)

Total length of activity = 20-25 minutes (7-10 minutes for each role-play and 5-6 minutes for a de-brief).

INSTRUCTIONS:

Break into pairs. In the first part of the exercise, one person will role-play an HIV provider (medical assistant, nurse, care manager, etc.) and the second person will role-play a patient. For this part, please refer to the “Repeat After Me” portion of the handout. Read from the script word for word.

The intention of part 1 is to give you practice getting comfortable screening for and talking with your patients about their alcohol use, and how this use may impact their HIV care.

Part 1: “Repeat After Me”

Conversation Opener – Setting the Stage for a Brief Intervention:

Provider: Good morning, my name is Jane and I am the nurse on duty today at the clinic. I would like to take a few minutes to talk with you about some questions you answered while you were waiting to see me. Is that ok with you?

Patient: Yeah, sure, why not. I’m here, so I’m not sure I even have a choice one way or the other.

Provider: Of course you have a choice. Would you be willing to have a quick conversation?

Patient: Yes.

Provider: Thank you, I appreciate your willingness to talk with me. We have a standard practice in the clinic to ask all patients a series of questions about their general health and a variety of behaviors that may positively or negatively impact their overall health and more specifically their HIV care. You answered a few questions about your alcohol use. Our conversation this morning will be focused on sharing information about the health risks that may be related to your alcohol consumption, ask you a bit more about your drinking, and discuss possible options for changing your alcohol use in the future.

Brief Intervention Step #1 – Provide Feedback

Provider: The screening instrument you completed is called the AUDIT. The 10 items featured on the AUDIT provide the health care team with information about your alcohol use and its impact on your health. Scores on the AUDIT can range from 0 to 40. People who do not drink at all receive a score of 0. To provide some context, about half of the individuals who live in the U.S. do
People who receive a score of 40 on the AUDIT may likely have a diagnosable alcohol use disorder and would benefit from a referral to specialty care. An AUDIT score of 0-7 indicates no or low-risk alcohol use. You scored a 19, which means that your drinking may be putting you at significant risk for a variety of health, social, and employment problems, and may impact the medications you are taking for HIV. What are your thoughts on this?

**Brief Intervention Step #2 – Listen and Understand**

**Patient:** Wow, a score of 19 seems high, there must be something wrong with the questionnaire. I totally do not think that my drinking is impacting my health in a negative way, and if I compare myself to my friends, I definitely drink a LOT less than any of them. They are the hot messes, not me.

**Provider:** Scores in the range of 16-19 usually indicate that the person’s alcohol consumption is high enough that they are likely to start to experience negative consequences like having trouble showing up to work, side-effects like bad hangovers or gastrointestinal issues, and taking their ART as prescribed. So maybe I’ll start by asking you about some of the things you like about drinking?

**Patient:** What’s not to like? First of all, I have a really stressful job, and having a few drinks after work helps me to chill out and decompress from the craziness of the work day. Plus, I get to meet up with my friends at the bar, and if I didn’t drink, they wouldn’t want to spend time with me. Oh, and it helps me get the courage to ask hot women for their digits. Well, not so much anymore, since I have a girlfriend, but it’s good to keep my options open, you know?

**Provider:** I hear you saying that alcohol use helps you to relax and be social with your friends. What else do you like about drinking?

**Patient:** I like the way it tastes. And I like the way it makes me feel, like I’m invincible without a care in the world. Remember what I said about my stressful job? Alcohol helps me to forget about the stress even if for a little while before reality sets back in.

**Provider:** It sounds like drinking helps you to come out of your shell and enjoy life outside of work. Is there anything else you’d like to say regarding the good things about drinking?

**Patient:** Nah, I think that covers it.

**Provider:** What are the not-so-good things about drinking?

**Patient:** That’s a tricky question to answer, let me think for a minute...Well, one thing that has been happening lately is that I’ve been sleeping through my alarm and showing up to work late. That leads to difficulty getting all my work done. I guess that is probably why things are so stressful at my job.

**Provider:** So your drinking as of late is impacting your productivity at work.
**Patient:** Yeah, and besides that, I’ve been getting into fights with my new girlfriend lately. She gets on my case and totally nags me about my drinking and I cannot deal with that right now.

**Provider:** Your romantic relationship is now being compromised by your drinking. Are there other things that are not-so-good about your drinking?

**Patient:** No, I think it’s really just the two things I already mentioned.

**Provider:** To summarize, on the one hand drinking helps you to decompress and spend time with your friends after work. On the other hand, your drinking is starting to cause problems with work and your girlfriend.

**Patient:** Yeah, I guess so.

**Brief Intervention Step 2, continued: Assessing Importance for Change**

**Provider:** Maybe a good next step in the conversation would be to talk a bit about how important it is to you to change your drinking. On a scale of 0 to 10, with 0 being not at all important, and 10 being the most important thing ever, what number would you choose?

**Patient:** Hmm, I’d say a 3.

**Provider:** Can you tell me why you didn’t pick the number 1?

**Patient:** Well, I just told you that my boss and girlfriend are on my case to stop drinking. So that’s annoying, and I’d love for them to knock it off.

**Provider:** What would it take to change your response to a 5?

**Patient:** I’d have to figure out something else I could do to be as relaxed as I am when I’m drinking with my buddies. Because stopping altogether is just not an option right now.

**Provider:** Given all of this, what do you think you might do next?

**Patient:** I definitely don’t want to quit drinking. I really don’t have a problem. I like to drink, and I can handle the fallout with my boss and girlfriend.

**Brief Intervention Step #3 – Options Explored**

**Provider:** Would it be ok with you if we explored a few things you might consider doing in the next few weeks?

**Patient:** Ok, sure. But don’t tell me I have to quit.

**Provider:** Some things you might consider are reducing the number of drinks you have in any given night, or maybe going out one fewer night and instead going to the gym or taking a yoga class, or something else that doesn’t involve drinking. It’s important to remember that alcohol can impact your compliance with taking your HIV meds (if you are drunk you are likely to forget
to take your meds), and alcohol can reduce the effectiveness of the medications that your body needs to fight your HIV infection.

**Patient:** I never really thought about, as I’m pretty good about taking my meds, and only forget every now and then.

**Provider:** So what do you think about the suggestions to drink less?

**Patient:** I guess I would be willing to try it out for week or two, but I’m not promising anything.

**Provider:** I understand. Luckily you have a follow-up appointment at the clinic in three weeks for us to repeat a few blood tests. Why don’t you try to cut back and we can chat about how it goes. Is there someone who can help you?

**Patient:** My girlfriend doesn’t drink so I can just spend more time with her instead of going to out to the bar during the week. She’ll like that a lot!

**Provider:** I want to thank you for your willingness to talk with me today. I cannot stress enough how important it is for you to be consistent in taking your HIV meds so that you can be as healthy as possible. If you need anything at all between now and your next appointment, please do not hesitate to call.

**Patient:** Thanks, I will.

The intention of part 2 is to give you even more practice getting comfortable screening for and talking with your patients about their alcohol use, and how this use may impact their HIV care. Over time, it will become easier for you to use your own words to explore alcohol use and its impact on HIV treatment with your patients.

**Part 2: “In Your Own Words”**

**Conversation Opener – Setting the Stage for a Brief Intervention**

- Introduce yourself and ask for permission to have a brief conversation

**Brief Intervention Step #1 – Provide Feedback**

- Provide AUDIT score and explain what the score means in terms of risk

**Brief Intervention Step #2 – Listen and Understand**

- Explore pros and cons of alcohol use (the good and not-so-good things)

**Brief Intervention Step 2, continued: Assessing Importance for Change**

- Explain importance of change, assess readiness to change (Readiness/Importance Ruler)
Brief Intervention Step #3 – Options Explored

- Discuss change options and plan for follow-up (Menu of options)

After part 2, you will be asked to participate in a full-group debrief with the entire audience.

- What did you like about this activity?
- What was challenging?
- How might you incorporate screening practices into your daily clinical work?